Vocal Biomarkers Progresses for Huge Profits by 2026


Sound vibrations are used as part of therapeutic healing for various mental health conditions such as depression and anxiety. Recent research studies, however, have greatly broadened its application into diagnosis of diseases. Biomarkers in the voice of a person have been linked to disorders such as depression, coronary artery disease, and anxiety. On successful completion of clinical trials, HIPAA compliant vocal biomarker system would serve as much more effective alternative to current diagnostic techniques such as MRI, X-Ray, and CT scan. Research is also underway for identifying vocal biomarkers in diagnosis of Parkinson’s disease, traumatic brain injury, cognitive impairment, and respiratory disorders, which would open up a highly lucrative avenue for growth for players in this industry. Companies dealing with voice technology are sampling data to provide accurate results. For instance, Beyond Verbal, Inc. has been researching on vocal biomarkers since 1996, and has collected over 2.5 million voice samples in over 40 different languages.

For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/101

While currently in its very nascent stage with an estimated value of US$ 6.4 million in 2017, the global vocal biomarkers market is expected to expand at a CAGR of 65.7% during the forecast period (2017 – 2028).

Growing Psychological and Cardiovascular Disease Prevalence: A Highly Conducive Growth Environment

Around 350 million people across the globe suffered from depression (WHO, 2016) and approximately 10 million people suffered from Parkinson’s disease globally (Parkinson’s disease Foundation, 2016). Over 235 million people suffered from asthma globally (2016), according to the European Respiratory Society. Diagnosis of these diseases is expensive and thus, is out of reach for most people in emerging economies. This results in high mortality rates in these regions. Vocal biomarker technology systems would act as an ideal cost-effective primary diagnostic tool that could help discern if the patient needs to further opt for expensive X-Ray/MRI/CT/EEG/ECG scans. Thus, millions of suffering from these chronic ailments explicates large potential for vocal biomarkers technology in the commercial space in the long run. Moreover, alterative conventionally used diagnostic systems need to adhere to stringent regulations pertaining to radiation. On the other hand, voice-based systems are based on technology that does not subject the user to any form of radiation and thus, is expected to gain significant traction in the near future.

Market Dynamics

Still in the clinical stage, the global vocal biomarkers technology would transform the way we mental and physical health is diagnosed and would transform the healthcare industry. This voice-based technology would allow for early diagnosis of diseases and accordingly help in taking preventive measures. This can significantly benefit military, hospitals and health clinics, and also individuals to monitor health and take appropriate medical action.

Key companies covered as a part of this study include Beyond Verbal, Inc., Cogito Corporation, Sonde Health, Sharecare, Inc., and IBM Corporation

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/101


About Author

Cynthia Carrier is a graduate of Texas A&M, where she played volleyball and annoyed a lot of professors. Now as Plains Gazette's entertainment and Lifestyle Editor, she enjoys writing about delicious BBQ, outrageous style trends and all things Texas.